Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 2/20 | 0.69 |
| ▸ | MGLL | Q99685 | 1/20 | 0.69 |
| ▸ | TGFBR1 | P36897 | 16/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5726000 | 0.89 | TGFBR1 (0.64) | STSMGLLTGFBR1 | |
| SCHEMBL7664865 | 0.89 | TGFBR1 (0.64) | MGLLTGFBR1 | |
| SCHEMBL16826195 | 0.89 | TGFBR1 (0.64) | STSMGLLTGFBR1 | |
| SCHEMBL14695860 | 0.89 | TGFBR1 (0.79) | TGFBR1 | |
| SCHEMBL25301261 | 0.87 | TGFBR1 (0.76) | STSMGLLTGFBR1 | |
| SCHEMBL5724845 | 0.86 | TGFBR1 (0.61) | MGLLTGFBR1 | |
| SCHEMBL15229274 | 0.86 | TGFBR1 (0.61) | MGLLTGFBR1 | |
| SCHEMBL25295874 | 0.86 | TGFBR1 (0.62) | STSMGLLTGFBR1 | |
| SCHEMBL20379479 | 0.86 | MGLL (0.54) | STSMGLLTGFBR1MEN1TSHR | |
| SCHEMBL12480436 | 0.85 | TGFBR1 (0.65) | STSMGLLTGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2576507-B1 | HEXAFLUOROISOPROPYL CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI SA (FR) | 2017-04-05 | — | — | EP | disclosed |
| US-8835418-B2 | Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application | SANOFI (FR) | 2014-09-16 | — | — | US | disclosed |
| US-20130165422-A1 | HEXAFLUOROISOPROPYL CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165422-A1 | HEXAFLUOROISOPROPYL CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | F7, MGMT, CA13 | STS 2853/4885MGLL 3200/4885TGFBR1 3576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.